Catherine J. Wu
Dana-Farber Cancer Institute
United States of America
Dr. Wu received her MD from Stanford University School of Medicine in 1994. She completed postgraduate training in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology and hematology at Dana-Farber/Partners CancerCare. In 2000, she joined Dana-Farber, where she is currently a member of the bone marrow transplant staff. Her research interests include the identification of targets of the immune response associated with therapies for hematologic malignancies.
Chronic lymphoblastic leukemia, Acute myeloid leukemia, Chronic myeloid leukemia, Stem cell transplantation, Sickle cell anemia, Tumor antigens
Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature 2017
Lazarian G, Guièze R, Wu CJ. Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol 2017
Purroy N, Wu CJ. Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med 2017.